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osting by EAbstract Spinal muscular atrophy (SMA) is characterized by progressive hypotonia and muscular
weakness because of progressive degeneration of alpha motor neuron from anterior horn cells in the
spinal cord. It is inherited by an autosomal recessive pattern. The precise frequency of SMA in Egypt
has not been determined. We tried to estimate the frequency, clinical and molecular characteristics of
SMA in Egypt. The study included all patients with SMAattended the Pediatric Hospital, Ain-Shams
University during the period (year 1966–2009). The study included 117 patients with SMA out of
660,280 patients attending the Pediatric Hospital. Patients selection was based on clinical examina-
tion, CPK, EMG, nerve conduction velocity, histopathology and molecular diagnosis. Frequency
of SMA was 17.7/100,000, which is considered high. Type I was the commonest type (60.6%), fol-
lowed by type II (26.79%), and type III (8.8%). Consanguinitywas reported in 45.5 and family history
in 47.8% of patients. Molecular study was done and 54.5% of patients (types I and II) have homozy-
gous deletion of exon 7, 36.3%ofwhomhad also homozygous deletion of exon 8 of SMN1genewhich
is considered lower than that reported in other countries. SMA is more prevalent in Egypt than in
many other countries. Forty-ﬁve percent of patients were chromosome 5-unlinked. We should con-
tinue to search for other mutation in Egypt to facilitate detection of carriers and prenatal diagnosis.
 2011 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.omanbay St., Hammamat El-
85577.
hoo.com (R.M. Shawky),
y. Production and hosting by
Shams University.
lsevier1. Introduction
Spinal muscular atrophy (SMA) is an autosomal recessive dis-
ease characterized by progressive hypotonia and muscular
weakness. The muscle weakness occurs because of progressive
degeneration of the alpha motor neuron from anterior horn
cells in the spinal cord leading to proximal and symmetrical
weakness and atrophy of limbs and trunk. In certain patients,
the motor neurons of cranial nerves (especially the CN V–CN
XII) are also involved. Sensations, which originates from the
posterior horn cells of the spinal cord is spared, as is intelligence.
Several muscles are also spared, including the diaphragm, the
26 R.M. Shawky, N.S. El-Sayedinvoluntary muscles of the gastrointestinal system, the heart
and sphincter [1–4].
According to age of onset and clinical severity, SMA is di-
vided into three types I–III. Type I (Werdnig–Hoffman dis-
ease). This acute infantile SMA is the most severe form. It is
usually identiﬁed from birth to 6 months. Affected children
never acquire the ability to sit and they usually die before
the second year from respiratory failure or aspiration pneumo-
nia. Type II (chronic infantile SMA or intermediate form) oc-
curs from 6 to 12 months of age and patients never stand.
Survival depends on the degree of respiratory muscle involve-
ment and death occurs after the second year. Type III (Kugel-
berg–Welander disease) is diagnosed in children 2–15 years.
Patients learn to walk but suffer from proximal muscle weak-
ness which results in scoliosis, wheelchair dependence and
death in adulthood [5]. The SMA gene is located on the long
arm of chromosome 5 (5q11.2-q13.3). The genes involved in
SMA are the survival motor neuron (SMN), the neuronal
apoptosis inhibitory protein (NAIP), the gene encoding p44
and the H4F5 gene. SMN gene is present in telomeric
(SMN1) and centromeric (SMN2) copies, within the SMN re-
gion. SMN1 and SMN2 genes can be distinguished by two sin-
gle nucleotide sequence variation in exons 7 and 8 [6].
More than 95% of patients with SMA have a homozygous
disruption in the SMN1 gene, caused by mutation, deletion, or
rearrangement. However all patients with SMA retain at least
one copy of SMN2, which generates only 10% of the amount
of full-length SMN protein versus SMN1. This genome organi-
zation provides a therapeutic pathway to promote SMN2, exist-
ing in all patients, so function like the missing SMN1 gene [7].
The incidence of SMA is about 1 in 10,000 live births with a car-
rier frequency of 1:50 [8,9]. Egypt enjoys a distinguished geo-
graphical location at the juncture of the ancient world
continents of Africa, Asia and Europe. Egypt is about 1 mil-
lion (m) km2 and is located in the north-eastern corner of Africa
and Southwestern Asia. On its northern coasts lies the Mediter-
ranean and on its eastern coasts lies the red sea. It is bounded on
the south by Sudan and on the West by Libya [10].
Egypt is divided into 26 governorates: four urban (Cairo,
Alexandria, Portsaid and Suez) with no rural populations.
The other 22 have both urban and rural areas. Nine of the
mixed governorates are in the Nile Delta (Lower Egypt) and
eight in the Nile Valley (Upper Egypt), while the remaining ﬁve
frontier governorates are the eastern and western boundaries
of Egypt. Cairo, the most populous Arab country, is the glori-
ous capital of Egypt, the cradle of civilization and the beacon
of religion. Cairo’s population rose to more than 18 millions
(the highest population density in Egypt), although ﬁgures sug-
gested large scale migration has ended. Egyptians are mainly
descended from ancient Egyptian Society (94%). Ethnic
minorities in Egypt include, Nubians, Berbers, Bedouin Arabs,
Beja and Dome (4%) and others (2%) [10].
We conducted a study to determine the frequency, clinical
and molecular characteristics of spinal muscular atrophy
(SMA) in the Genetics Clinic, Pediatric Hospital, Faculty of
Medicine, Ain-Shams University, as it is one of the main refer-
ral centers in Egypt. This hospital is located in the northeast
section of Cairo [11]. It has a good reputation and high stan-
dard of health care so nearly all patients in this area attend this
hospital for consultation. Also patients come nearly from all
governorates to take good health care in this hospital. So the
frequency and characteristics of SMA will represent the fre-quency and characteristics of this disease in the general popu-
lation to a great extent.2. Subjects and methods
This study was conducted from January 1966 to December
2009. The sources from which cases were ascertained came
from retrospective surveys of medical records in the Genetics
Unit, Pediatric Hospital during this period, as well as
various studies published in national and international
journals.
We intended to identify all patients with spinal muscle atro-
phy attended the hospital during the period of the study (117
patients among 28,689 patients attended the Genetics Clinic
and 660,280 patients attended the Pediatric Hospital). Patients
selection was based on history, pedigree analysis, clinical
examination and investigations including CPK, EMG, nerve
conduction velocity, histopathology and molecular diagnosis
(available in last 10 years only) using single strand conﬁrma-
tion polymorphism analysis [12]. The age of studied patients
ranged from 1.5 months to 7 years and 6 of them were adults
aged 30–36 years. Forty-eight patients were males and sixty-se-
ven patients were females (0.7–1). The sample was divided into
three groups according to the age of onset and rate of progres-
sion of the disease:
Group I – acute infantile SMA: age of onset before
6 months and rapidly progressive. This group included 79
patients.
Group II – chronic childhood SMA: onset after the age of
6 months and slowly progressive. This group included 32
patients.
Group III – adult type: Onset in the third decade of life and
showing slow progression. This group included 6 patients.3. Results
One hundred and seventeen patients with spinal muscle atro-
phy attended the Genetics Clinic out of 627 patients with neu-
romuscular disorders and 660,280 patients attended the
Pediatric Hospital during the period of the study. Spinal mus-
cle atrophy thus constituted 18.66% of neuromuscular disor-
ders and 17.7/100,000 of patients attending the Pediatric
Hospital. Sluggish fetal movements and kicking in utero were
reported by the mothers of all type I patients. Other details of
prenatal, natal and postnatal history were found to be irrele-
vant. A family history was reported in 56 families (47.8% of
patients). Consanguinity was reported in 54 families (46% of
patients).
The most common complain were recurrent chest infection,
hypotonia and weakness in all type I patients (67.5%) second-
ary inability to walk in all type II patients (27.3%), and weak-
ness and difﬁculty in walking in all type III patients (5.2%). All
type I patients presented with profound weakness and hypoto-
nia, but wasting was not marked because of early death. Deep
reﬂexes were absent, sensations were intact and mentality was
normal. Tongue fasciculations were prominent and hand trem-
ors were present in the second and third groups of patients.
CPK was normal or slightly elevated in all patients. EMG
showed neurogenic pattern and nerve conduction velocity
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vere SMA, but the atrophic group of both ﬁber types appeared
to be smaller in the chronic form of the disease.
Molecular study was done for 33 patients and showed 18
patients (55%) to have homozygous deletion of exon 7, 12 of
whom (36%), also had homozygous deletion of exon 8. All
of these patients had SMA types I or II. Another 12 patients
(36%), had either a homozygous deletion of both exons 7
and 8, or both exons were normal. These patients also be-
longed to SMA types I and II. The three patients with the
adult type SMA (9%) were either heterozygous or normal
for exon 7 and heterozygous for an abnormally sized atypical
exon 8 [13].4. Discussion
SMA constituted 18.66% of neuromuscular disorders and
0.02% of all patients attending the Pediatric Hospital (17.7/
100,000). This frequency is higher than that reported/100,000
in USA (5–7) [14], in Germany (9) [15], in Italy (7–8) [14], in Po-
land (5) [14], in England (4) [14], in SaudiArabia (4.5) [16] and in
Libya (0.3) [17]. This may be due to high consanguinity rate re-
ported in this study (47.8%) compared to that reported among
the general population in Egypt (38.9%) [18]. These data reveal
the importance of lowering the consanguinity rate and the value
of genetic counseling andprenatal diagnosis in preventing SMA.
Also considerable variations in prevalences and incidence in dif-
ferent countries may be due to genetic differences.
In this study type I was the commonest type (67.6%), fol-
lowed by type II (27.3%) and type III (5.1%). The same was
also previously reported in Egypt (13) [19] as well as in many
other Arabic and European countries [20–24]. 47.8% of Egyp-
tian SMA families had a positive family history of similarly af-
fected members. A report from Hungary gave a rate of 32%
[25]. In the Egyptian familial cases, the age of onset was very
similar and all affected family members belonged to the same
type of SMA. However another study by Rudnik-Schoneborn
et al. suggested that other SMA types such as I and III can fre-
quently be observed among the siblings of patients with SMA
type II, another argument in favour of a continuous spectrum
in childhood SMA [26].
Males are more commonly affected than females (2:1) and
the clinical course is more severe in males [27], although in this
study as well as in another Egyptian study females were more
commonly affected than males 0.7:1 [13]. Zerres and Rudnik-
Schoneborn, suggested that there may be a female sparing fac-
tor, responsible for the marked decrease in number of affected
girls in late onset group [28]. However no signiﬁcant effect of
sex was established by Rudnik-Schoneborn et al. [26].
Molecular study of SMA Egyptian patients [13] revealed
that the frequency of homozygous deletion of exons 7 and 8
or exon 7 alone of SMN1 gene was present in 54.5% irrespec-
tive of clinical severity [13]. In another Egyptian study, 80% of
studied patients have either homozygous absence of SMN1
exons 7 and 8 or exon 7 alone [19]. A larger molecular study
in Egypt could resolve this controversy. Another interesting
ﬁnding in an Egyptian study is that all patients with absence
of exon 8 had also absence of SMN1 exon 7. Independent of
clinical severity, homozygous deletion of SMN1 gene has been
demonstrated in up to 98% of patients with SMA many ethnic
groups [29–33]. Vander Steege et al. [34] have reported homo-zygous deletion of SMN1 gene in 98.6% of Dutch patients
with SMN and Shafeghati et al. [35] detected homozygous
deletion in 95% in Iranian population. Also 96.4% of SMA
German patients display homozygous absence of SMN exons
7 and 8 or exon 7 only, where as 3.6% present compound het-
erozygosity with a subtle mutation on one chromosome and a
deletion/gene conversion on the other chromosome. Among
the 23 different subtle mutations described, the Y27 2C mis-
sense mutation is the most frequent one, at 20%. The number
of SMN2 copies modulated SMA phenotype. Nevertheless, it
should not be used for prediction of severity of the SMA
[36]. Nighty four percent of SMA Saudi [37] and 100% of
Kuwaiti [38] patients demonstrated deletion of SMN1 gene.
Exon 5 of NAIP was homozygously absent in all type I Kuwa-
iti patients, but was retained in type II cases [38].
In terms of genotype–phenotype correlation there is a
higher incidence of homozygous absence of both exons 7 and
8 of SMN1 gene in Egyptian patients with the severe type I
(42.9%) compared to type II patients (33.3%) [13]. However
in another Egyptian study the frequency of homozygous ab-
sence of SMN1 exons 7 and 8 or exon 7 alone was higher
(100%) in patients with mildest form of disease compared to
those with the severest (80%) and the intermediate forms
(67%). These results are similar to that reported by other stud-
ies [39–41]. Also in South African blacks SMA patients, the
frequency of homozygous absence of exons 7 and 8 was higher
in types II/III than in type I [42]. A higher incidence of homol-
ogous deletions of exons 7 and 8 of SMN1 gene and exon 5 of
NAIP gene were detected in all Kuwaiti type II patients and
exon 5 of NAIP gene in only one type II patient. This latter
patient had associated Pierre Robin syndrome [43]. Another
interesting ﬁnding in an Egyptian study is that all patients with
absence of exon 8 had also absence of SMN1 exon [19]. The
same result was also reported by several studies [44–49].
The deletion of NAIP gene was found in 45% of Egyptian
SMA patients [19]. The frequency of the deletion was more fre-
quent in type I patients (80%) as compared to type II (22%)
and type III (50%). In Kuwaiti [38] and Saudi Arabian pa-
tients [45], the incidence was even higher (100%). Thus higher
frequencies of NAIP gene deletions were found in Arab popu-
lations compared to populations of other ethnic groups [50].
Relatively lower incidence (66–68%) was reported for Spanish
[44], Finnish [51], Turkish [49] and Chinese [52]. Japanese pa-
tients showed even lower incidence (17–40%) [39].
A notable result obtained in Egypt is the higher frequency
of E5 deletion in type III (50%), than in type II (22%) SMA
patients [19]. Similar results have also been reported by two
other studies in Spanish [44] and Finnish [51] patients, respec-
tively. The correlation of the deletion and clinical severity is
obvious thus justifying the use of this information for progno-
sis and genetic counseling [19].
SMA1 gene has been linked to pre-mRNA splicing, splice-
osome biogenesis, and the nucleolar protein ﬁbrillin. The ab-
sence or dysfunction of SMN is reﬂected by an enhanced
neuronal death. A heterozygous deletion leads to an asymp-
tomatic carrier state [38]. The SMN2 gene is not interrupted
in 95% normal and SMA chromosomes. The other candidate
gene (NAIP), shows homozygous deletions in 45–67% of type
I and 20–42% of type II and type III patients. Deletions of
NAIP5 and SMN1 exon 7 have been associated with a 5-fold
increased risk of type I SMA. NAIP gene mutation can lead
to extensive neuronal cell death at the onset of the disease thus
28 R.M. Shawky, N.S. El-Sayedmodifying the clinical presentation of SMA into the severe
form. Furthermore in type I patients lacking NAIP gene the
deterioration in respiratory function was more rapid than in
type I patients retaining NAIP gene [39].
A commonly used polymerase chain reaction/restriction
fragment length polymorphism (PCR–RFLP) assay can be
used to detect a homozygous absence of SMN 1 exon 7.
SMN gene dosage analysis, which can determine the copy
numbers of SMN1 and SMN2 (an SMN1 homolog and a mod-
iﬁer for SMA), have been developed for SMA carrier testing.
Linkage analysis remains an important component of SMA
genetic testing in certain circumstances. Haplotype analysis
also may be widely used [53,54].
There is no effective cure or treatment for SMA and the
recurrence risk is 25% for high risk families. Thus, the availabil-
ity of prenatal testing is important. Savas et al. using direct diges-
tion analysis of SMN1 gene by restriction digestion
demonstrated that a carefulmolecular analysis of the SMNgene
is very useful in predicting the phenotype of the fetus in families
at risk [55].
Forty-ﬁve percent in this study and 20% in another study of
Egyptian SMA patients did not show homozygosity for a dele-
tion in SMN1 gene exon 7. These patients have been diagnosed
based on international consortium criteria [56]. Also in Ger-
many 4% of SMA patients are unlinked to chromosome 5q13
[36]. SMA patients who did not show deletions of SMN exons
7 and 8 or 7 only were clinically indistinguishable from deleted
patients [42]. Also homozygous deletions of SMN gene exons 7
and 8 was found in one unaffected mother of type II SMA pa-
tient, as well as in six further unaffected individuals, all sibs of
types II and III. So these families were regarded as chromosome
5 unlinked. This suggests that other genes or mechanisms may
be necessary to produce SMA phenotype [42]. Also Novelli
et al. [57] observed 2 sibs affected by the severe neonatal form
of SMA with diaphragmatic paralysis that were discordant
for the haplotypes determined by DNA markers ﬂanking the
SMA locus. This supports non-linkage of SMA to chromosome
5 in this family and indicated that the uncommon SMA type I
variant associated with early onset respiratory failure maps
outside the 5q11.2-q13.3. Alsaman and Tomoum [58] present
the ﬁrst genetically proven case of infantile spinal muscular
atrophy with respiratory distress type I from Saudi Arabia. It
is an unusual variant of spinal muscular atrophy type I that
is characterized by early respiratory failure due to diaphrag-
matic paralysis. The defective gene is the immunoglobulin l-
binding protein 2 (IGH MBP2 gene) which is located on chro-
mosome 11q13 and encodes l-binding protein 2.
SMA has a carrier frequency of 1:33–1:60 in most popula-
tions. Carrier screening was carried out among residents of an
isolated Israeli Arab Village with a high frequency of SMA to
identify carriers of SMA type I and SMA with respiratory dis-
tress I (SMARDI). However, 13.1% were found to be carriers
of SMA and 9.9% for SMARDI [59]. In Saudi Arabia carrier
frequency was 1:20 was also reported which is considered very
high [60].
To conclude the frequency of SMA among Egyptians is high
and carrier frequency should be considered in Egypt in a pop-
ulation based screening program as it is expected to be high. As
there is no cure for this disease, genetic counseling becomes
very important in disease management. We should continue
to search for other mutations in Egypt to facilitate detection
of carriers and presymptomatic cases especially those unlinkedto chromosome 5. SMN gene dosage analysis, and linkage anal-
ysis, combined with appropriate genetic risk assessment and ge-
netic counseling, offers the most important complete evaluation
of SMA patients and their families [53].
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